Simvastatin Tablet, Film Coated
Product Images NDC 71610-615

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Simvastatin (NDC 71610-615). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 10 mg (71610 0615 45)

Bottle Label 10 mg (71610 0615 45)
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Footnote For Table 3 (Footnote For Table 3)

Footnote For Table 3 (Footnote For Table 3)
This text provides information on the results of chemical assays for CYP3Ad inhibitors such as ketoconazole, erythromycin, clarithromycin, HIV, protease inhibitors, and nefazodone. It also explains the meaning of simvastatin acid, and mentions that the effects of different amounts of grapefruit juice on simvastatin pharmacokinetics have not been studied thoroughly. The text describes the administration of grapefruit juice and simvastatin at different strengths and times, with simvastatin administered on the third day.*
FDA Label Image

Figure 9 (Simvastatin 10)

Figure 9 (Simvastatin 10)
FDA Label Image

Table2 (Simvastatin 2)

Table2 (Simvastatin 2)
This is a table showing the adverse reactions reported by patients treated with Simvastatin compared to placebo. The table shows the percentage of patients that reported each reaction regardless of whether it was related to the medication or not. The reactions are grouped by body system, including body as a whole, cardiovascular, digestive, endocrine, musculoskeletal, nervous system/psychiatric, respiratory, skin/skin appendage, and urogenital system disorders. Some of the reactions that were reported more frequently in patients taking Simvastatin than in those taking placebo include edema/swelling, atrial fibrillation, constipation, diabetes mellitus, myalgia, and eczema.*
FDA Label Image

Structure (Simvastatin 3)

Structure (Simvastatin 3)
FDA Label Image

Table 3 (Simvastatin 4)

Table 3 (Simvastatin 4)
FDA Label Image

Table 4 (Simvastatin 5)

Table 4 (Simvastatin 5)
FDA Label Image

Figure 5 (Simvastatin 6)

Figure 5 (Simvastatin 6)
This appears to be a table displaying characteristics, patient counts, and risk ratios of major vascular events and major coronary events. The table is comparing the effectiveness of Simvastatin versus a Placebo in reducing the risk of these events in patients with or without certain conditions such as peripheral vascular disease and coxibzovascular disease. The exact values for risk ratios are not available as they only provide confidence intervals.*
FDA Label Image

Figure 6 (Simvastatin 7)

Figure 6 (Simvastatin 7)
FDA Label Image

Figure 7 (Simvastatin 8)

Figure 7 (Simvastatin 8)
The description is: "The text is not-readable."*
FDA Label Image

Figure 8 (Simvastatin 9)

Figure 8 (Simvastatin 9)
FDA Label Image

Table 1 (Table1)

Table 1 (Table1)
This text contains a table listing drug interactions that are associated with an increased risk of MyopathyRhabdomyolysis, along with prescribing recommendations for each interaction. It includes drugs like CYP3A4 inhibitors, HIV protease inhibitors, verapamil, diltiazem, amiodarone, and others with corresponding dosage recommendations or precautions. The text is readable and informative.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.